4.7 Article

Pneumococcal Pneumonia Mechanisms of Infection and Resolution

Journal

CHEST
Volume 142, Issue 2, Pages 482-491

Publisher

ELSEVIER
DOI: 10.1378/chest.12-0210

Keywords

-

Funding

  1. Wellcome Trust Senior Clinical Fellowship [076945]
  2. Wellcome Trust
  3. Medical Research Council (MRC) grants
  4. European Community's Seventh Framework Programme [HEALTH-F3-2009-223111]
  5. Medical Research Council (MRC)
  6. MRC
  7. ViiV Healthcare
  8. Gilead
  9. Bristol-Myers Squibb
  10. Merck Sharp Dohme Corp
  11. Janssen-Cilag Pty Limited
  12. Novartis AG

Ask authors/readers for more resources

Vaccination and antimicrobial therapy remain the cornerstones of the management of pneumococcal pneumonia. Despite significant successes, the capacity of the pneumococcus to evolve in the face of the selective pressure of anticapsular immunity challenges immunization programs. Treatment focuses on antimicrobial therapy but ignores the central role of the dysregulated inflammatory response during pneumonia. Future therapeutic approaches need to build on the considerable recent advances in our understanding of the pathogenesis of pneumococcal pneumonia, including those from models of pneumonia. Enhancement of the essential components of the host response that prevents most colonized individuals from developing pneumonia and strategies to limit inappropriate inflammatory responses to lower respiratory tract infection are approaches that could be exploited to improve disease outcome. This review highlights recent discoveries relating to the microbial and host determinants of microbial clearance and regulation of the inflammatory response, which provide clues as to how this could be achieved in the future. CHEST 2012; 142(2):482-491

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available